# US 2015/0031738 A1 · Cyclic compounds and methods of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031738 A1
- Document ID: US20150031738A1
- Status: Published application
- Kind: A1
- Application number: 14/365,148
- Filed: 2012-12-10
- Published: 2015-01-29
- Earliest claimed: 2011-12-13
- Assignees: University of Massachusetts
- Applicants: Cellceutix Corporation; University of Massachusetts
- Inventors: Yan Li; Hitest Thaker; Gregory N. Tew; Dahui Liu; Wenxi Pan
- Web page: https://patentgrep.com/patent/US20150031738A1

## CPC

- C07D 249/06: with aryl radicals directly attached to ring atoms
- A01N 39/00: Biocides, pest repellants or attractants, or plant growth regulators containing aryloxy- or arylthio-aliphatic or cycloaliphatic compounds, containing the group [IMAGE cpc-sch-A01N-0940.gif] or [IMAGE cpc-sch-A01N-0941.gif], e.g. phenoxyethylamine, phenylthio-acetonitrile, phenoxyacetone
- A01N 43/38: condensed with carbocyclic rings
- A01N 43/647: Triazoles; Hydrogenated triazoles
- A01N 47/44: Guanidine; Derivatives thereof
- C07C 217/04: the carbon skeleton being acyclic and saturated
- C07C 217/16: the six-membered aromatic ring or condensed ring system containing that ring not being further substituted
- C07C 279/02: Guanidine; Salts, complexes or addition compounds thereof
- C07C 279/08: being further substituted by singly-bound oxygen atoms
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 209/12: Radicals substituted by oxygen atoms
- C07D 295/135: with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.

## Claims

### Claim 1

A compound of Formula II
wherein:
X is
R1 is H,
R2 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R3 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R4 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R5 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R6 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4; and
R7 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
or a pharmaceutically acceptable salt thereof; or
a compound of Formula I
wherein:
X is
R1 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R2 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R3 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R4 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R5 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R6 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4; and
R7 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
or a pharmaceutically acceptable salt thereof; or
a compound of Formula III
wherein:
X is
R1 is H,
R2 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R3 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R4 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R5 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R6 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4; and
R7 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
or a pharmaceutically acceptable salt thereof; or
a compound of Formula IV
wherein:
R1 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R2 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R3 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R4 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R5 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
R6 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —CH≡CH—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4; and
or a pharmaceutically acceptable salt thereof; or
a compound of Formula V:
R1-A1-X—Z—X-A1-R2 (V)
or a pharmaceutically acceptable salt thereof,
wherein:
each X is, independently, —NR8, —N(R8)N(R8)—, O, or S, wherein each R8 is, independently, hydrogen or alkyl;
each Z is, independently, C═O, C═S, or O═S═O;
each A1 is, independently, aryl optionally substituted with one or more W, or heteroaryl optionally substituted with one or more W;
each W is, independently, —CF3, halo, C1-4alkyl, —O—(CH2)1-5NHC(═NH)NH2, —N((CH2)1-5—NH2)((CH2)1-5N(C1-4alkyl)2), —N((CH2)1-5N(C1-4alkyl)2)2, heterocycle, —S—(CH2)1-5NHC(═NH)NH2, —S—(CH2)1-5NH2, —S—(CH2)1-5N(CH3)2, —C1-4alkyl, —S—(CH2)1-5NHS(═O)2—C1-4alkyl, O-heterocycle (wherein the heterocycle is optionally substituted with one or more cyano, amino, C1-4alkyl, C1-4alkoxy, guanidino, hydroxyl, amidino, or halo); and
R1 and R2 are, independently, hydrogen, halo, —NO2, —S—(CH2)1-5NHC(═NH)NH2, —O—(CH2)1-5NHC(═NH)NH2, —CF3, —N+(═O)O−, —(CH2)1-5NHC(═NH)NH2, amino, —S—(CH2)1-5N(CH3)2, —O—(CH2)1-5N(CH3)2, —O-heterocycle (wherein the heterocycle is optionally substituted), —S-heterocycle (wherein the heterocycle is optionally substituted), —NHC(═O)—C1-4alkyl, —NHC(═O)—(CH2)1-5NHC(═NH)NH2, —NHC(═O)—(CH2)1-5-aryl (wherein either or both the —(CH2)1-5 or phenyl is optionally substituted), —NHC(═O)—(CH2)1-5NH-aryl (wherein either or both —NH and/or aryl is optionally substituted), —NHC(═O)-aryl (wherein the aryl is optionally substituted), or —NHC(═O)—(CH2)1-5NHS(═O)2—C1-4alkyl, wherein the optional substituents are chosen from one or more cyano, amino, C1-4alkyl, guanidino, hydroxyl, amidino, C1-4alkoxy, CF3, and halo.

### Claim at position 2

2-11. (canceled)

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof chosen from

### Claim at position 4

13-88. (canceled)

### Claim 89 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 90 (depends on 89)

The composition of claim 89 further comprising an excipient chosen from purified water, propylene glycol, polyethyleneglycol (PEG) 400, glycerin, DMA, ethanol, benzyl alcohol, citric acid/sodium citrate (pH3), citric acid/sodium citrate (pH5), tris(hydroxymethyl)amino methane HCl (pH7.0), 0.9% saline, and 1.2% saline, or any combination thereof.

### Claim 91 (depends on 89)

The composition of claim 89 further comprising an excipient chosen from propylene glycol, purified water, and glycerin.

### Claim 92 (depends on 89)

The composition of claim 89 further comprising an excipient chosen from 20% w/v propylene glycol in saline, 30% w/v propylene glycol in saline, 40% w/v propylene glycol in saline, 50% w/v propylene glycol in saline, 15% w/v propylene glycol in purified water, 30% w/v propylene glycol in purified water, 50% w/v propylene glycol in purified water, 30% w/v propylene glycol and 5 w/v ethanol in purified water, 15% w/v glycerin in purified water, 30% w/v glycerin in purified water, 50% w/v glycerin in purified water, 20% w/v Kleptose in purified water, 40% w/v Kleptose in purified water, and 25% w/v Captisol in purified water.

### Claim 93 (depends on 89)

The composition of claim 89 further comprising an excipient chosen from 50% w/v propylene glycol in purified water, 15% w/v glycerin in purified water, 20% w/v Kleptose in purified water, 40% w/v Kleptose in purified water, and 25% w/v Captisol in purified water.

### Claim 94 (depends on 89)

The composition of claim 89 further comprising an excipient chosen from 20% w/v Kleptose in purified water, 20% w/v propylene glycol in purified water, and 15% w/v glycerin in purified water.

### Claim 95 (depends on 1)

A method of inhibiting the growth of a microbe or inhibiting the growth of a Mycobacterium species comprising contacting the microbe or species with a compound, or pharmaceutically acceptable salt thereof, of claim 1.

### Claim 96 (depends on 1)

A method of treating a mammal having a microbial infection, treating a mammal having a Mycobacterium infection, treating oral mucositis in a mammal, antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative in a mammal, inhibiting anti-Factor Xa in a mammal, treating a microbial infection in an eye or ear of a mammal, treating or reducing cancer in a mammal, inhibiting growth of a cancer cell in a mammal, inhibiting tumor growth in a mammal, reducing spread or metastasis of cancer in a mammal, or modulating an immune response in a mammal, comprising administering to the mammal in need thereof an anti-microbial effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 1.

### Claim at position 13

97-140. (canceled)
